{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-003939","form_type":"8-K","ticker":"STOK","cik":"0001623526","company_name":"Stoke Therapeutics, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.845037+00:00","generated_at":"2026-06-07T02:19:52.095315+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Stoke Therapeutics details 2024 clinical milestones; STK-001 data in Q1, STK-002 trial in UK","bullets":["In Q1 2024, plans to report safety, PK, and CSF results from 81 patients in STK-001 Phase 1/2a and OLE studies.","Seizure frequency data from ~20 patients who received 1-3 doses of 70mg STK-001, followed for six months, will be released in Q1.","Repeat dose effects (30mg, 45mg) on seizure frequency and cognition/behavior from OLE studies also expected in Q1.","Depending on Q1 results, plans to start Phase 3 preparation including regulatory discussions and toxicology data.","Phase 1 study of STK-002 for Autosomal Dominant Optic Atrophy expected to begin in UK in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-003939","json":"https://secwatch.observer/filing/0001193125-24-003939.json","markdown":"https://secwatch.observer/filing/0001193125-24-003939.md","text":"https://secwatch.observer/filing/0001193125-24-003939.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1623526/000119312524003939/0001193125-24-003939-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1623526/000119312524003939/d39993d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:19:52.095315+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}